Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05024305Phase 1Unknown

Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.

Role: lead

NCT04871347Phase 1Unknown

The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor

Role: lead

NCT04871334Phase 1Unknown

Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma

Role: lead

NCT04878705Phase 1Unknown

Safety and Tolerability of TWP-201 in Healthy Female Subjects

Role: lead

All 4 trials loaded